{"schema_version":"secwatch.filing_event.v1","accession":"0001326110-25-000031","form_type":"8-K","ticker":"IBRX","cik":"0001326110","company_name":"ImmunityBio, Inc.","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.306917+00:00","generated_at":"2026-05-25T17:01:46.164807+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ImmunityBio Q4 net product revenue $7.2M; Feb ANKTIVA units up 67% MoM; RMAT designation granted","bullets":["Net product revenue $7.2M in Q4 2024, up 21% QoQ from $6.0M in Q3; full-year net product revenue $14.2M.","ANKTIVA February 2025 unit sales up 67% month-over-month from January; Jan+Feb combined exceed total Q4 2024 units.","Permanent J-code (J9028) issued Jan 2025; FDA authorized expanded access of rBCG with over 45,000 vials available and 60+ sites activating.","MAAs for ANKTIVA+BCG accepted by MHRA and EMA in Feb 2025; RMAT designation for ANKTIVA+PD-L1 t-haNK in pancreatic cancer.","Net loss attributable to common stockholders narrowed to $59.2M in Q4 2024 from $233.4M in Q4 2023; cash and securities $149.8M at Dec 31."],"urls":{"canonical":"https://secwatch.observer/filing/0001326110-25-000031","json":"https://secwatch.observer/filing/0001326110-25-000031.json","markdown":"https://secwatch.observer/filing/0001326110-25-000031.md","text":"https://secwatch.observer/filing/0001326110-25-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000031/0001326110-25-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000031/ibrx-20250303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T17:01:46.164807+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}